Selective Sodium Channel Modulators for Pain Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sodium channel blockers for pain management lack subtype selectivity, leading to significant CNS and cardiovascular side effects due to their non-specific action on Nav1.x channels, necessitating the development of potent and selective inhibitors for Nav1.7, Nav1.3, Nav1.8, and Nav1.9 to improve pain treatment efficacy while minimizing side effects.
Innovation Solution
Development of compounds of formula (I) and their pharmaceutical compositions, which exhibit subtype and functional selectivity in modulating voltage-gated sodium ion channels, specifically targeting Nav1.7, Nav1.3, and Nav1.9 to treat pain disorders with reduced CNS and cardiovascular side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective sodium channel blockers are used for pain management, then pain relief is achieved, but CNS and cardiovascular side effects occur due to lack of subtype selectivity
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I) that selectively bind to particular Nav1.x channel subtypes (particularly Nav1.7, Nav1.3, Nav1.8, and Nav1.9) rather than blocking all sodium channels uniformly. This subtype-selective binding allows the drug to exert its pain-relieving effect on specific neuronal populations while sparing other tissues expressing different channel subtypes, thereby reducing off-target side effects.
Solution Approach 2:
The invention segments the broad class of sodium channels into distinct subtypes (Nav1.1 through Nav1.9) with different tissue distributions and functional roles. By developing compounds that selectively target specific subtypes involved in pain transmission (particularly peripheral sensory neuron subtypes), the patent achieves differentiated action that separates therapeutic effects from harmful side effects on CNS and cardiovascular systems.
2Adaptability or versatility
If broad-spectrum sodium channel blockers are administered, then comprehensive pain coverage is provided, but dose range is limited due to side effects from interfering with multiple channel functions
Solution Approach 1:
The compounds of formula (I) exhibit local quality through their selective affinity for specific Nav1.x subtypes, allowing them to address multiple pain conditions mediated by these subtypes without requiring high doses that would cause off-target effects. This enables a wider therapeutic window and greater dose range flexibility compared to non-selective blockers.
3Reliability
If high potency sodium channel blockers are used to ensure effective pain relief, then analgesic effect is enhanced, but selectivity for specific Nav1.x subtypes is reduced
Solution Approach 1:
The patent resolves this contradiction by designing compounds with local quality - high potency selective binding to specific Nav1.x subtypes (particularly Nav1.7, Nav1.3, Nav1.8, and Nav1.9) rather than uniform moderate potency across all subtypes. The molecular structure of formula (I) is optimized to achieve both high affinity for target subtypes and sufficient pharmacological activity, eliminating the need to trade off selectivity for potency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively treat various pain conditions, including neuropathic and inflammatory pain, with improved subtype selectivity, reducing the risk of CNS and cardiovascular side effects, thereby providing a more targeted and effective pain management solution.
Implementation Method 1
Voltage gated sodium channels are essential for the initiation and propagation of action potentials in excitable tissues such as muscle and nerve. Pharmacological, molecular and genetic studies in both human and rodents, have identified several channels as pivotal for pain signal transmission, including Nav1.3, Nav1.7, Nav1.8, and Nav1.9.
Data Source
AI summary
The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.